Abstract

BackgroundGroup B Streptococcus (GBS) remains susceptible to penicillin, however, resistance to second-line antimicrobials, clindamycin and erythromycin, has increased since 1996. We describe the age-specific antibiotic susceptibility profile and capsular type distribution among invasive and colonizing GBS strains.MethodsWe tested 486 invasive GBS isolates from individuals of all ages collected by a Wisconsin surveillance system between 1998 and 2002 and 167 colonizing strains collected from nonpregnant college students during 2001 in Michigan. Antimicrobial susceptibility testing was performed by disk diffusion or Etest and capsular typing was performed using DNA dot blot hybridizationResults20.0% (97/486) of invasive and 40.7% (68/167) of colonizing isolates were resistant to clindamycin (P < .001) and 24.5% (119/486) of invasive and 41.9% (70/167) of colonizing isolates were resistant to erythromycin (P < .001). Similarly, 19.8% (96/486) of invasive and 38.3% (64/167) of colonizing isolates were resistant to both antimicrobial agents (P < .001). 29.4% (5/17) of invasive isolates from persons 18–29 years of age and 24.3% (17/70) of invasive isolates from persons 30–49 years of age were resistant to clindamycin. Similarly, 35.3% (6/17) of invasive isolates from persons 18–29 years of age and 31.4% (22/70) of invasive isolates from persons 30–49 years of age were resistant to erythromycin. 34.7% (26/75) of invasive isolates from persons < 1 year of age were capsular type Ia, whereas capsular type V predominated among isolates from adults.ConclusionClindamycin and erythromycin resistance rates were high among isolates colonizing nonpregnant college students and invasive GBS isolates, particularly among the colonizing isolates. Susceptibility profiles were similar by age although the proportion of clindamycin and erythromycin resistance among invasive isolates was highest among persons 18–49 years of age. Increasing antimicrobial resistance has implications for GBS disease treatment and intrapartum prophylaxis among penicillin intolerant patients.

Highlights

  • Group B Streptococcus (GBS) remains susceptible to penicillin, resistance to second-line antimicrobials, clindamycin and erythromycin, has increased since 1996

  • We examined the antimicrobial susceptibility profile and capsular type distribution for 486 invasive GBS isolates and 167 isolates colonizing nonpregnant adults

  • minimum inhibitory concentration (MIC) ranges were similar for colonizing strains. 20.0% (97/486) of invasive and 40.7% (68/167) of colonizing isolates were resistant to clindamycin (P < .001) and 24.5% (119/486) of invasive and 41.9% (70/167) of colonizing isolates were resistant to erythromycin (P < .001). 37.1% (36/97) of invasive and 20.6% (14/68) of colonizing isolates resistant to clindamycin were identified by D-test

Read more

Summary

Introduction

Group B Streptococcus (GBS) remains susceptible to penicillin, resistance to second-line antimicrobials, clindamycin and erythromycin, has increased since 1996. Group B Streptococcus (GBS) (Streptococcus agalactiae) is a significant cause of neonatal sepsis and meningitis and of severe infections in pregnant women and nonpregnant adults with underlying medical conditions [1]. The prevalence of GBS colonization among pregnant and nonpregnant adults has been estimated at 10% to 40% [2,3,4]. Administration of intrapartum antimicrobial prophylaxis (IAP) to colonized women has resulted in a striking decline in cases of early-onset and maternal GBS disease [6]. A similar decrease has not been observed for infants with late-onset disease or nonpregnant adults; currently there is no established prevention protocol for either group

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.